Kinase Inhibitors: Global Markets

Kinase Inhibitors: Global Markets published by BCC Research in November, 2009. This report consists of 184 pages and the price starts from US $ 4850.

Introduction

Abstract

• Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014
• An overview of the market for the kinase inhibitor class of drugs that already are approved and in development, and on the rapidly growing market for kinase inhibitors in key indications, such as cancer and inflammatory disorders
• Discussions of the factors such as regulatory issues, the rapidly-changing competitive marketplace, new technologies, and managed-care issues that will affect sales of kinase inhibitors
• Detailed company profiles and an evaluation of recent patents.

SCOPE OF REPORT

The scope of this study encompasses technologies employed in the pharmacogenomics industry. For each kinase inhibitor type in clinical use, BCC has analyzed the evidence of efficacy, technical limitations, and current market status and presents forecasts of growth over the next 5 years. We have emphasized the potential for additional novel applications and new competitive threats. We examine the role of government regulations, patents, and factors affecting the industry worldwide. In addition, we analyze how the development of new kinase inhibitors is translating into new medical therapies for specific disease targets.

METHODOLOGY

The market assessments provided have been assembled based on publicly available information from January 2006 up to and including October 2009. The base year for this report is 2009 and forecast data are provided through 2014. In cases where data for 2009 were not available, figures were extrapolated from 2008 statistics, half-year figures for 2009, and historical trends between 2005 and 2008. Market figures are based on current dollars, and inflation is not computed into the projection figures. Interviews were also used to adjust market size estimates as well as to formulate market projections.

The field of kinase inhibitor development is still immature and the reader is cautioned to use the report data as a guide to assess trends, developments, and challenges that the industry faces.

INFORMATION SOURCES

The information contained in this report has been assembled from both primary and secondary data. Primary research was conducted via in-person, telephone, and e-mail interviews with selected industry professionals, research scientists, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports, and industry press releases.

AUTHOR' S CREDENTIALS

Brian Lawler has more than 4 years of experience working as an analyst covering the pharmaceutical and biotechnology industries. Trained at the University of Southern California, he holds a B.A. degree in economics.

Table of Contents

Kinase Inhibitors: Global Markets

Chapter- 1: INTRODUCTION -- Complimentary

• STUDY GOALS AND OBJECTIVES
• REASONS FOR DOING THIS STUDY
• INTENDED AUDIENCE
• SCOPE OF REPORT
• METHODOLOGY
• INFORMATION SOURCES
• AUTHOR' S CREDENTIALS
• RELATED BCC WORK CREDENTIALS
• BCC ONLINE SERVICES
• DISCLAIMER

Chapter-2: SUMMARY

• SUMMARY
• SUMMARY TABLE GLOBAL FORECAST OF THE KINASE INHIBITORS (RT, NRT, AND S/T) MARKET BY TYPE, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL FORECAST OF THE KINASE INHIBITORS MARKET BY TYPE, 2006- 2014 ($ MILLIONS)

Chapter-3: OVERVIEW

• THE CELLULAR ROLE OF KINASES
• INHIBITORS OF PROTEIN KINASES
• INHIBITORS OF PROTEIN KINASES (CONTINUED)
• KINASES AS ATTRACTIVE DRUG TARGETS
  • TABLE 1 ATTRACTIVE FEATURES OF PROTEIN KINASES
• KINASE INHIBITORS IN CLINICAL USE AND CLINICAL TRIALS
  • TABLE 2 FDA-APPROVED KINASE INHIBITORS
  • TABLE 3 KINASE INHIBITORS IN CLINICAL TRIALS, ORDERED BY PHASE
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)
  • TABLE 4 NUMBER OF KINASE INHIBITORS IN CLINICAL TRIALS, BY PHASE
  • TABLE 5 COMPANIES WITH KINASE INHIBITORS IN CLINICAL TRIALS
  • TABLE 5 (CONTINUED)
• DATABASES AND LARGE-SCALE INITIATIVES
  • TABLE 6 KINASE DATABASES
• KINBASE
• KINASENET
• KINASE SEQUENCE DATABASE (KSD)
• KINMUTBASE
• SCANSITE
• KINASE PATHWAY DATABASE

Chapter-4: TECHNOLOGY OVERVIEW

• DEVELOPMENT PROCESS
• TYPES OF KINASE INHIBITORS
  • TABLE 7 COMPARISON OF TYPES OF INHIBITORS
• SMALL MOLECULE KINASE INHIBITORS
  • TABLE 8 COMPARISON OF ATP COMPETITIVE AND NONCOMPETITIVE INHIBITORS
• ATP COMPETITIVE INHIBITORS
• NON-ATP COMPETITIVE INHIBITORS
• MONOCLONAL ANTIBODIES
• ISSUES OF SPECIFICITY
• ISSUES OF SPECIFICITY (CONTINUED)
• PROTEIN STRUCTURE AND MODELING
• RATIONAL DESIGN

Chapter-5: PATENT EVALUATION

• PATENT SHARE BY KINASE TYPE
  • TABLE 9 KINASE INHIBITOR PATENTS BY TARGET MOLECULE, JULY 2006 TO JULY 2009 (NUMBER)
  • TABLE 10 U.S. AND EU APPROVED KINASE INHIBITORS MAJOR PATENT/EXCLUSIVITY EXPIRATION DATES
  • TABLE 11 KINASE INHIBITOR PATENTS BY ASSIGNEE (NUMBER)
  • TABLE 11 (CONTINUED)

Chapter-6: MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS

• TOTAL MARKET SIZE
  • TABLE 12 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • FIGURE 1 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, 2006- 2014 ($ MILLIONS)
• RECEPTOR TYROSINE KINASE BIOLOGY
• EGFR/HER FAMILY PROTEIN KINASES (EGFR, HER2, HER3, AND HER4)
• OVERVIEW
  • TABLE 13 EGFR FAMILY INHIBITORS BY STAGE OF CLINIAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS)
• EGFR INHIBITORS IN CLINICAL USE
• Erbitux (Cetuximab)
• Erbitux (Cetuximab) (Continued)
• Tarceva (Erlotinib)
• Tarceva (Erlotinib) (Continued)
• Iressa (Gefitinib)
• FDA APPROVAL IN THE UNITED STATES
• FAST TRACK APPROVAL IN JAPAN
• POST-MARKET STUDIES OF IRESSA
• Vectibix (Panitumumab)
• Nimotuzumab
• GLOBAL MARKET FOR EGFR INHIBITORS
  • TABLE 14 GLOBAL MARKET FOR EGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS)
• EGFR INHIBITORS IN DEVELOPMENT
• Tovok (BIBW 2992)
• Neratinib (HKI-272)
• Zactima (Vandetanib, ZD6474)
• Zalutumumab (HuMax-EGFr)
• IMC-11F8
• BMS-690514
• HER2 INHIBITORS
• IN CLINICAL USE
• Herceptin (Trastuzumab)
• Tykerb/Tyverb (Lapatinib)
• HER2 INHIBITORS IN CLINICAL DEVELOPMENT
• ARRY-380
• INSM-18
• GLOBAL MARKET FOR HER2 INHIBITORS
  • TABLE 15 GLOBAL MARKET FOR HER2 INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS)
• Global Market for HER2 Inhibitors (Continued)
• VEGF RECEPTOR FAMILY INHIBITORS
• OVERVIEW
  • TABLE 16 VEGFR FAMILY INHIBITORS BY STAGE OF CLINIAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS)
• VEGF RECEPTOR INHIBITORS IN CLINICAL USE
• Nexavar (Sorafenib)
• Sutent (Sunitinib)
• Palladia (Toceranib)
• VEGFR INHIBITORS IN DEVELOPMENT
• Axitinib (AG-013736)
• Motesanib (AMG 706)
• Recentin (Cediranib, AZD2171)
• Vargatef (BIBF 1120)
• Pazopanib (GW786034)
• Ramucirumab (IMC-1121B)
• Vatalanib (PTK787, ZK222584)
• Brivanib (BMS-582664)
• XL184 (BMS-907351)
• XL880 (GSK1363089)
• ABT-869
• GLOBAL MARKET FOR VEGFR INHIBITORS
  • TABLE 17 GLOBAL MARKET FOR VEGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS)
• PDGF RECEPTOR FAMILY INHIBITORS
• OVERVIEW
  • TABLE 18 PDGFR FAMILY INHIBITORS BY STAGE OF CLINIAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS)
• PDGFR FAMILY INHIBITORS IN DEVELOPMENT
• Masitinib (AB1010)
• Tandutinib (MLN518, CT53518)
• IMC-3G3
• INS RECEPTOR FAMILY INHIBITORS
• OVERVIEW
• INS RECEPTOR FAMILY INHIBITORS IN DEVELOPMENT
• Figitumumab (CP-751871, CP-751, 871)
• AMG-479

Chapter-7: MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS

• TOTAL MARKET SIZE AND BACKGROUND
  • TABLE 19 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • FIGURE 2 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET, 2006- 2014 ($ MILLIONS)
• ABL KINASES
• OVERVIEW
• ABL INHIBITORS IN CLINICAL USE
• Gleevec
• Tasigna (Nilotinib, AMN107)
• ABL INHIBITORS IN DEVELOPMENT
• AT9283
• AP24534
• Bafetinib (INNO-406)
• KW-2449
• XL228
• GLOBAL MARKET FOR ABL INHIBITORS
  • TABLE 20 GLOBAL FORECAST FOR ABL INHIBITORS MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
• Global Market for ABL Inhibitors (Continued)
• SRC KINASES
• OVERVIEW
• SRC KINASE INHIBITORS IN CLINICAL USE
• Sprycel (Dasatinib, BMS-354825)
• SRC KINASE INHIBITORS IN DEVELOPMENT
• Bosutinib (SKI-606)
• AZD0530
• KX2-391
• JAK KINASES
• OVERVIEW
• JAK INHIBITORS IN DEVELOPMENT
• CP-690
• INCB18424
• INCB28050
• Lestaurtinib (CEP-701)
• ONX 0803 (SB1518)
• TG101348
• FAKS
• OVERVIEW
• FAK INHIBITORS IN DEVELOPMENT
• PF-00562271
• PF-04554878

Chapter-8: MARKET FOR SERINE/THREONINE KINASE INHIBITORS

• TOTAL MARKET SIZE
  • TABLE 21 GLOBAL FORECAST FOR THE STKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • FIGURE 3 GLOBAL FORECAST FOR THE STKI MARKET, 2006- 2014 ($ MILLIONS)
• MTOR KINASE INHIBITORS
• OVERVIEW
• MTOR INHIBITORS IN CLINICAL USE
• Rapamune (Sirolimus)
• Certican, Afinitor (Everolimus, RAD001)
• Certican, Afinitor (Everolimus, RAD001) (Continued)
• Torisel (Temsirolimus)
• GLOBAL MARKET FOR MTOR INHIBITORS
  • TABLE 22 GLOBAL MARKET FOR MTOR INHIBITORS* BY REGION, THROUGH 2014 ($ MILLIONS)
• IN DEVELOPMENT
• Ridaforolimus, Deforolimus (MK-8669, AP23573)
• AZD8055
• BEZ235
• BGT226
• OSI-027
• PF-04691502
• XL765
• RHO FAMILY KINASE INHIBITORS
• OVERVIEW
• RHO KINASE FAMILY INHIBITORS IN CLINICAL USE
• Eril (Fasudil Hydrochloride)
• RHO KINASE FAMILY INHIBITORS IN DEVELOPMENT
• Cethrin (BA-210)
• SAR407899A
• DE-104
• Y-39983, RKI-983
• GLOBAL MARKET FOR RHO-KINASE INHIBITORS
  • TABLE 23 GLOBAL MARKET FOR RHO-KINASE INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS)
• CYCLIN DEPENDENT KINASES
• OVERVIEW
• CDK INHIBITORS IN CLINICAL DEVELOPMENT
• Alvocidib (Flavopiridol, HMR1275)
• Seliciclib (CYC202, Roscovitine)
• P276
• AT7519
• PD-0332991
• P1446
• PROTEIN KINASE C
• OVERVIEW
• PKC INHIBITORS IN CLINICAL DEVELOPMENT
• Enzastaurin (LY317615)
• Midostaurin (PKC412)
• Sotrastaurin (AEB071)
• KAI-9803
• KAI-1678
• PI3K
• OVERVIEW
• PI3 KINASE INHIBITORS IN CLINICAL DEVELOPMENT
• AZD6482
• BKM120
• CAL-101
• CAL-263
• GDC-0941 (RG7321)
• GDC-0980 (RG7422)
• PX-866
• SF1126
• XL147
• AURORA KINASES
• OVERVIEW
• AURORA KINASE INHIBITORS IN CLINICAL DEVELOPMENT
• AZD1152
• MLN8237
• PHA-739358
• CYC116
• MK-5108 (VX-689)
• R763 (AS703569)
• SNS-314
• TAK-901
• MAP/MEK KINASES
• OVERVIEW
• MEK/P38 INHIBITORS IN CLINICAL DEVELOPMENT
• AZD6244
• ARRY-797
• BMS-582949
• Losmapimod (GW856553)
• JUN N-TERMINAL KINASES (JNK)
• OVERVIEW
• JNK INHIBITORS IN CLINICAL DEVELOPMENT
• Perifosine (KRX-041)

Chapter-9: MARKET FOR KINASE INHIBITORS BY DISEASE APPLICATION

• TOTAL MARKET SIZE
  • TABLE 24 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY CURRENT APPLICATIONS, THROUGH 2014
• CURRENT APPLICATIONS
• CANCER
• Market Size by Kinase Inhibitors
  • TABLE 25 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CANCER TREATMENT BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • TABLE 26 KINASE INHIBITORS APPROVED TO TREAT CANCER INDICATIONS
• Types of Cancer
• Lung Cancer
• EGFR Inhibitors for Lung Cancer Treatment
• VEGFR Inhibitors for Lung Cancer
• Breast Cancer
• ERB/HER2 Inhibitors for Breast Cancer Treatment
• Colorectal Cancer
• EGFR Inhibitors for Colorectal Cancer
• Pancreatic Cancer
• EGFR Inhibitors for Pancreatic Cancer Treatment
• Other Kinase Inhibitors for Pancreatic Cancer
• Skin Cancers
• Basal Cell Carcinoma
• Squamous Cell Carcinoma
• Melanoma
• EGFR Inhibitors for Skin Cancer Treatment
• MAPK/ERK Inhibitors for Skin Cancer Treatment
• PI3K Inhibitors for Skin Cancer Treatment
• Ras/Raf Inhibitors in Skin Cancer Treatment
• Kidney Cancer
• Kinase Inhibitors in Kidney Cancer
• Sarcoma
• Kinase Inhibitors for GIST
• Liver Cancer
• Kinase Inhibitors in Liver Cancer
• Leukemias
• Chronic Myeloid Leukemia
• Acute Myeloid Leukemia
• BCR-ABL Inhibitors for Leukemia Treatment
• Flt3 Inhibitors for Leukemia Treatment
• IMMUNE AND INFLAMMATORY DISEASES
• MARKET SIZE BY KINASE INHIBITORS
  • TABLE 27 WORLDWIDE MARKET FOR KINASE INHIBITORS IN IMMUNE AND INFLAMMATORY DISEASE BY PRODUCT, THROUGH 2014 ($ MILLIONS)
• Immunosuppression for Organ Transplantation
• mTOR Inhibitors for Immunosuppression
• Asthma
• MAPK Inhibitors in Asthma Treatment
• Arthritis
• MAPK Inhibitors in Arthritis Treatment
• CARDIOVASCULAR DISEASE
• MARKET SIZE BY KINASE INHIBITORS
  • TABLE 28 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CARDIOVASCULAR DISEASE TREATMENT BY PRODUCT, THROUGH 2014 ($ MILLIONS)
• Rho Kinases for Cardiovascular Disease
• MAPK Inhibitors for Cardiovascular Treatment
• MAPK Inhibitors for ... (Continued)
• MEK/MAPK1 Inhibitors for Cardiovascular Disease
• JNK inhibitors for Cardiovascular disease
• EMERGING APPLICATIONS
• DIABETES
• VEGF Inhibitors for Treatment of Diabetes
• FLT3 Inhibitors for Treatment of Diabetes
• PKC Inhibitors in the Treatment of Diabetes
• MACULAR DEGENERATION
• VEGF Inhibitors for Macular Degeneration
• NEUROLOGICAL DISEASE
• GSK Kinase Inhibitors for Neurological Disease
• CDK Inhibitors for Neurological Disease

Chapter-10: MAJOR COMPANIES AND MARKET SHARE

• MARKET SHARES
  • TABLE 29 KINASE INHIBITOR SALES AND MARKET SHARE OF COMPANIES INVOLVED IN KINASE INHIBITORS, 2008 ($ MILLIONS/%)
  • TABLE 30 SALES AND MARKET SHARE OF COMPANIES INVOLVED IN TKI, 2008 ($ MILLIONS/%)
• COMPANY PROFILES
• AB SCIENCE
• AB Science USA
• AMGEN
• ARIAD PHARMACEUTICALS
• ARRAY BIOPHARMA
• ASTEX THERAPEUTICS
• ASTRAZENECA
• Astrazeneca - U.S. Headquarters
• AVEO PHARMACEUTICALS
• BAYER AG
• Bayer - U.S. Location
• BOEHRINGER INGELHEIM
• Boehringer Ingelheim Pharmaceuticals, Inc.
• BRISTOL-MYERS SQUIBB
• CEPHALON, INC.
• CYCLACEL PHARMACEUTICALS
• Cyclacel - U.S. Location
• ELI LILLY
• EXELIXIS
• GENMAB
• Genmab - U.S. Location
• GLAXOSMITHKLINE
• GlaxoSmithKline - U.S. Location
• INCYTE
• KAI PHARMACEUTICALS
• MERCK KGAA (MERCK SERONO)
• NOVARTIS
• Novartis Institutes for BioMedical Research, Inc.
• ONYX PHARMACEUTICALS
• OSI PHARMACEUTICALS
• PFIZER
• ROCHE (F. HOFFMANN-LA ROCHE, LTD.)
• SANOFI-AVENTIS
• TAKEDA
• TARGEGEN
• VERTEX PHARMACEUTICALS
• WYETH

Chapter-11: INTERNATIONAL ASPECTS AND REGULATORY ISSUES

• MARKET BY REGION
  • TABLE 31 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY REGION, THROUGH 2014 ($ MILLIONS)
  • FIGURE 4 REGIONAL SHARE OF GLOBAL MARKET FOR KINASE INHIBITORS, BY REGION 2008 AND 2014 (%)
• UNITED STATES
• DRUG WITHDRAWALS
• MEDICARE
• OTHER HEALTHCARE CHANGES
• EUROPEAN UNION
• NEW DRUG APPROVALS AND INNOVATION
• DRUG REIMBURSEMENT AND REFERENCE PRICING
• RELOCATION OF R&D
• REGULATORY CLIMATE
• JAPAN
• NEW DRUG APPROVALS
• REGULATORY CLIMATE
• RELATIONSHIP OF ACADEMIA AND INDUSTRY
• VENTURE CAPITAL

Chapter-12: FUTURE DIRECTIONS

• SPECIFICITY AND COMPLEXITY
• RESISTANCE
• KINASE ACTIVATORS
• DEVELOPMENTS IN ENABLING TECHNOLOGIES
• PHOSPHORYLATION-STATE ANTIBODIES
• Phosphorylation-State Antibodies (Continued)
• HIGH-THROUGHPUT KINASE ASSAYS
• HIGH-THROUGHPUT KINASE ASSAYS(CONT)

Related Reports